Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
AlzChem Group AG is a vertically integrated specialty chemicals company with roots dating back to 1908, renowned for its leadership in niche markets including Health & Pharma, Human & Animal Nutrition, Renewable Energies, Agriculture, Metallurgy, Fine Chemistry, Automotive & Defense, and Custom Manufacturing. The company specializes in high-quality, innovative products derived from the calcium carbide/calcium cyanamide chain, known as the NCN chain, utilizing basic inputs like lime, coal, and electricity to produce over 900 registered brands ranging from basic chemicals to complex specialties. Key offerings include the premium Creapure brand for high-purity creatine monohydrate in sports nutrition, the feed additive Creamino for animal growth, and Nitroguanidine for energetic applications in defense. Operating four production sites in Germany's East Bavarian chemical triangle (Trostberg, Schalchen, Hart, Waldkraiburg) and one in Sundsvall, Sweden, AlzChem employs around 1,725 people and generated 554.2 million EUR in sales in 2024. Its business is structured into Specialty Chemicals (59% revenue), Basics & Intermediates (36%), and Other & Holding, serving a diversified global customer base across Europe, North America, and Asia, addressing global challenges like climate change, nutrition, and security.
€157.90
+€0.70 (+0.45%)
EOD Aug 7, 2026
16.54% operating margin is respectable but not wide. ROIC at 23.91%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue growth slowed to 1.4%, essentially flat. This is a business that needs a catalyst.
Even for strong businesses, today's 24x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
23.9x earnings, 12.8x FCF. Valuation is in a reasonable range. The main question is whether the business can re-accelerate or if current trajectory is already priced in.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€566M
▲ +1.4% YoY
Net Income (TTM)
€67M
▲ +17.3% YoY
Op. Margin
17.27%
▲ +2.4pp YoY
ROIC
23.91%
▲ +0.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€125M
▲ +30.3% YoY
Op. Cash Flow (TTM)
€125M
▲ +30.3% YoY
Net Debt
-€32M
Net Cash Position
Cash & Equiv.
€76M
3Y CAGR: +1.2%
Continue Research
At a P/E of 23.9 and a price-to-free-cash-flow of 12.8, AlzChem Group (ACT.XETR) trades below a two-stage DCF intrinsic value of about €627.25 per share, so at €157.90 the stock looks undervalued (297.2% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, AlzChem Group scores 80/100 on Intrinsiqq's quality scorecard (a high-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 1.1%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about €627.25 per share for ACT.XETR, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around €470.44. At today's €157.90, that puts the stock about 297.2% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
AlzChem Group scores 80 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a high-quality business on these measures. Recent fundamentals include a 17.3% operating margin and a 23.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, AlzChem Group pays a regular dividend of about €1.80 per share per year (typically in quarterly installments), a yield of roughly 1.1% at the current price. That is a payout ratio of about 27.2% of earnings, so the dividend is amply covered by earnings. AlzChem Group has grown the dividend at roughly 23.5% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For ACT.XETR's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. ACT.XETR currently trades below its estimated intrinsic value and scores 80/100 on quality (high-quality). It also yields about 1.1%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.